Ester Industries — Q2 & H1 FY27 — 5 November 2026

1. Overall Tone of Management

Cautious. Management is positive on the film industry’s demand and the company’s year-on-year turnaround, but the tone is tempered by a sharp decline in specialty-polymer sales, higher working-capital needs, rising debt, and uncertainty around Elite’s partner funding and land acquisition. Some forward-looking claims—such as raw-material “insulation” and confidence in Elite—are notably strong relative to the risks discussed.

2. Key Themes from Management Commentary

BOPET recovery, helped by demand and exports: Management said the industry’s Q1 improvement continued in Q2, with better domestic and export demand. Exports were about 37% of revenue; US exports revived after tariff disruption eased.
Film profitability improved year on year, but remains cyclical: Film revenue rose 39.6% on 13.9% volume growth, reflecting higher realizations and a better mix. Segment EBIT turned positive at ₹34.5 crore versus a ₹6.2 crore loss a year earlier. However, consolidated EBITDA fell sequentially to ₹45.1 crore from ₹58.9 crore in Q1.
Value-added films are the central strategic shift: VAS and specialty films reached 26% of Q2 volume and 27% in H1. Management targets about 35% by Q4 FY27 and 50–60% over two to three years, with customer approvals the main bottleneck.
Specialty polymers face a material product-specific setback: Revenue fell 49% year on year as demand eroded for a marquee high-margin product after a major customer moved to different chemistry. Management expects new products to offset some lost volume, but much of the recovery is later-dated.
Higher working capital is offsetting debt repayment: Higher raw-material and freight costs, longer transit times, and increased inventory and receivables raised working-capital needs. Gross borrowings rose to ₹748.8 crore despite term-loan repayments.
Elite remains a long-dated opportunity with execution and funding risks: The JV has completed FEED and appointed a detailed engineering firm; Nike is an anchor customer. Land acquisition remains pending, and Loop’s equity funding depends on milestones and private-equity commitments.

3. Q&A Analysis

Film margins, cycle resilience and raw-material pass-through

Analysts asked: Are film margins sustainable given raw-material volatility and cyclicality? What is the outlook for Chinese imports, anti-dumping duties, and spreads?
Management responded: Indian BOPET demand is growing 8–10% annually, while capacity additions are expected to lag demand. Management said overcapacity should not recur for “the next 8 to 10 quarters.” It argued that raw-material increases can be passed through and that VAS products will improve resilience.
Notable qualification: The anti-dumping duty was only recommended; management expected government notification by end-December. The demand and capacity outlook is confident, but policy relief remains uncertain.
Quote: “We are therefore largely insulated from volatility in raw material prices.”

Film mix and margin targets

Analysts asked: What could prevent the planned VAS mix increase, and what margin improvement might follow?
Management responded: Customer approvals are the main delay. It reiterated the 35% VAS target by Q4 FY27 and 50–60% over two to three years. At the higher mix, management’s internal target is a sustainable 15% EBITDA margin.
Unusually strong answer: Management said the mix shift should bring EBITDA margins into the “respectable teens,” while giving no interim margin bridge.

Specialty-polymer decline and new-product pipeline

Analysts asked: Why did a specialty product lose demand, how concentrated is the business, and when can new products compensate?
Management responded: The largest customer changed its technology/process and moved to a different chemistry. Management acknowledged dependence on a small number of high-margin products, while saying it now sells 7–8 product types, serves 15–16 customers, and has 27 customers evaluating 8–9 products.
Timing and economics: Some value-added products may begin ramping next quarter; one new product could reach roughly 200 tonnes/month after six to nine months, but is mid-margin. The redesigned product for the lost application is in a full approval cycle and may take 1.5–2 years. Management said recovery from the lost volumes is expected mainly in Q4 FY27 and into FY28.
Direct admission: “You are absolutely right that this business relies on 2 products and that there are risks.”
Caveat: The 25% specialty-polymer CAGR target is now based on FY27 as the base year, after management acknowledged that recovering prior-year revenue levels this financial year will be difficult.

Elite: Loop funding, land, economics and schedule

Analysts asked: Could Loop fail to fund its share, is a plan B needed, and is the project delayed?
Management responded: Loop has private-equity commitments conditional on milestones; Elite has in-principle approval for a term loan, with final sanction expected in three to four months. Management said land possession is expected in Q1 calendar 2027 and denied project delay.
Project economics: Management cited 45,000 tonnes annual capacity, ₹1,200–1,400 crore capex, and 40–45% EBITDA margins, with a significant portion of capacity covered by customer commitments.
Risk / answer quality: Management was emphatic—“Absolutely” no plan B is needed—but Loop’s funding was described as committed rather than already funded, and land acquisition remains outstanding. The confidence is stronger than the evidence disclosed on the call.

Debt, working capital and H2 outlook

Analysts asked: Why did debt rise despite repayments, what is leverage, and how should investors model H2?
Management responded: ₹53.5 crore of term loans was repaid in H1 against a full-year target of about ₹100 crore. Debt rose because working capital increased; management expects that pressure to ease if raw-material and freight conditions stabilize. Net debt/EBITDA was estimated at 3–3.25, with a target of 2–2.25 but no timeline.
Outlook: H2 film results are expected to be similar to or slightly better than H1; specialty polymers are expected to be slightly better than H1.
Evasive/partial: The leverage estimate was uncertain during the call, and no specific timetable was given for reaching the target.

4. Guidance / Outlook

Quantitative guidance
– VAS/specialty films: approximately 35% of film volumes by Q4 FY27, then 50–60% over two to three years.
– Film EBITDA: internal target of sustainable 15% EBITDA margin at a 50–60% specialty-film mix.
– Specialty polymers: approximately 25% revenue CAGR over three to five years, with FY27 as the base year.
– Specialty-polymer recovery: partial recovery expected in coming months; much of the lost-volume recovery expected in Q4 FY27 and FY28. H2 FY27 expected to be slightly better than H1.
– Films H2 FY27: similar to or slightly better than H1.
– Debt: full-year FY27 term-loan repayment target of approximately ₹100 crore; ₹53.5 crore repaid in H1.
– Capex: ₹15.1 crore incurred in H1; going forward, no major capex planned beyond maintenance and marginal capex for new specialty-polymer products.
– Elite: 45,000 tonnes per year capacity, ₹1,200–1,400 crore project capex, 40–45% EBITDA margin, and commercial operations targeted for Q4 calendar 2028.
– Anti-dumping duty: management expected notification by end-December, but this is a policy expectation, not a confirmed outcome.

Qualitative signals
– Management expects the film-industry environment to remain stable medium to long term, supported by demand growth, moderate capacity additions, recycled-content regulation and revived exports.
– Working-capital requirements are expected to ease if raw-material and freight conditions stabilize.
– Elite’s additional debt would remain at JV level and would not be consolidated line by line.
– Specialty-polymer product approvals and customer qualification remain key timing risks.

5. Standout Statements

“We expect that for the next 8 to 10 quarters, the overcapacity situation should not recur.”
“Our internal target is to bring it to a sustainable 15% EBITDA margin profile.”
“You are absolutely right that this business relies on 2 products and that there are risks.”
The lost specialty product was affected by a customer’s “technology change and a process change,” not simply short-term ordering.
Management said a substantial part of specialty-polymer recovery would occur in “the last quarter of FY27 and into the next financial year.”
“Absolutely” no plan B is needed for Loop’s equity contribution, despite the analyst’s concerns about Loop’s financial condition.
“But for the increased requirement for working capital, we would have seen a reduction in debt during H1 FY27.”

6. Red Flags / Positive Signals

Red flags
– Specialty-polymer revenue fell 49% in Q2; H1 revenue fell 41%. The high-margin product loss reflects a customer chemistry change, and replacement products have approval and ramp-up lead times.
– Gross borrowings rose to ₹748.8 crore; net working capital increased by ₹66.7 crore in H1, partly funded by short-term borrowings.
– Elite land acquisition and Loop equity funding remain unresolved; customer commitments do not remove construction, financing or execution risk.
– The 15% film EBITDA goal and near-term cycle outlook depend on mix improvement, approvals, and the industry supply-demand balance.

Positive signals
– Consolidated EBITDA rose 160% year on year to ₹45.1 crore and PAT returned to profit.
– Film VAS volume grew 25.8% year on year; H1 VAS volume reached a record.
– Ester Filmtech has been profitable every quarter since Q4 FY26.
– US exports have revived; management says Indian exporters’ tariff treatment is now comparable to that of other exporting countries.

7. Historical Comparison & Consistency Analysis

Q2 FY26 — 17 November 2025

Dominant tone: Pessimistic
Major themes this quarter:
Chinese imports and US tariffs pressuring film margins.
Specialty polymers growing strongly and supporting profitability.
Recycling and Elite positioned as long-term growth opportunities.
Tone shift vs previous quarter: N/A (baseline)
What changed: N/A (baseline)

Q3 FY26 — 9 February 2026

Dominant tone: Pessimistic
Major themes this quarter:
Film performance described as near the bottom of the cycle.
US tariff relief and anti-dumping duty expected to support recovery.
Specialty polymers presented as a strong “profit anchor”; Elite land and financing still in progress.
Tone shift vs previous quarter: More Cautious
What changed:
Weak consolidated profitability and low utilization made the cycle downturn more visible.
Recovery remained dependent on expected tariff and anti-dumping relief.
Management still forecast strong specialty-polymer growth.

Q4 FY26 — 15 May 2026

Dominant tone: Optimistic
Major themes this quarter:
Film margins and demand described as having reached an inflection point.
FY27 framed as significantly stronger, with VAS growth and cost savings expected.
Elite offtake agreements and project progress emphasized.
Tone shift vs previous quarter: More Optimistic
What changed:
Management said major film headwinds had moderated and expected margin improvement.
It forecast improving profitability and debt reduction in FY27.
Specialty polymers were still expected to grow about 20% annually, with ₹200 crore revenue described as achievable.

Q2 FY27 — 5 November 2026

Dominant tone: Neutral
Major themes this quarter:
Film recovery and VAS mix expansion supported by demand, exports and recycled-content requirements.
Specialty polymers reset by lost demand at a major customer; new products expected to offset it over time.
Working-capital growth and debt reduction remain priorities; Elite construction and funding milestones continue.
Tone shift vs previous quarter: More Cautious
What changed:
Film performance improved year on year, but management acknowledged the specialty-polymer decline will make FY27 revenue recovery difficult.
The 25% specialty-polymer growth ambition was rebased to FY27, rather than presented as near-term continuation of prior growth.
Debt increased in H1 despite repayments, and land acquisition for Elite remains pending.
Comparison caveat: Q1 FY27 transcript was not provided; this block compares with the latest supplied prior call, Q4 FY26.

Trajectory Summary: Management moved from describing severe external pressures in Q2–Q3 FY26 to a confident recovery narrative in Q4 FY26. In the current call, the film recovery is visible, but the narrative has become more qualified: specialty-polymer concentration risk, working-capital pressure and Elite execution are harder to overlook.

b. Tracking Past Commitments vs Outcomes

Past statement: Q4 FY26 management expected Specialty Polymers to grow around 20% and said ₹200 crore revenue in FY27 was achievable.
Expected: Continued growth and roughly ₹200 crore revenue.
What happened: H1 FY27 revenue was ₹62 crore, down 41% year on year; management said the prior level would be difficult to reach this year.
Flag: ❌ Missed / dropped for FY27 as previously framed.
Past statement: Q4 FY26 management expected a “significantly stronger FY27,” with film margin recovery.
Expected: Broad-based improvement.
What happened: Consolidated results improved sharply year on year, and film EBIT turned positive; however, Q2 EBITDA was down sequentially and specialty polymers weakened materially.
Flag: ✅ Delivered in year-on-year profitability; partial on breadth and sequential momentum.
Past statement: Q3 FY26 expected Elite land acquisition by April–May 2026; Q4 FY26 targeted commercial operations by end-2028.
Expected: Land secured in 2026 and operations in late 2028.
What happened: Land was still expected to be acquired by Q4 FY27, with possession expected in Q1 calendar 2027; commercial operations remain targeted for Q4 calendar 2028.
Flag: ⏳ Delayed on land; commercial-operation target retained.
Past statement: Q4 FY26 targeted FY27 debt reduction, with about ₹85 crore annual repayment and expectations of lower closing debt.
Expected: Gross debt to fall during FY27.
What happened: ₹53.5 crore of term loans was repaid in H1, but borrowings rose to ₹748.8 crore due to working-capital funding. Full-year reduction remains management’s objective.
Flag: ⏳ Not yet delivered; at risk pending working-capital normalization.
Past statement: Ester Filmtech had turned around in Q4 FY26.
Expected: Sustained operating improvement.
What happened: It reported profit in every quarter since Q4 FY26, including Q2 FY27.
Flag: ✅ Delivered.
Past statement: VAS film share was about 25% in FY26, with a target of 50–60% over two to three years.
Expected: Continued mix improvement.
What happened: VAS was 26% in Q2 and 27% in H1 FY27; the 35% Q4 FY27 target remains ahead.
Flag: ✅ Progressing; target not yet due.

c. Narrative Shifts

From broad film recovery to differentiated growth: Management now places greater emphasis on VAS mix and customer qualification as protection against cyclicality, rather than relying mainly on industry pricing and anti-dumping relief.
Specialty polymers shifted from growth anchor to concentration risk: Earlier calls emphasized IP-protected products and growth; the current call openly acknowledges reliance on two marquee products and a customer’s switch to different chemistry.
Elite has moved from strategic promise to execution and funding scrutiny: Customer offtake remains a positive, but land, Loop’s equity contribution and project economics are more prominent.
Working capital and leverage now feature more prominently: They have become a constraint on debt reduction even as operating profitability improves.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management provides useful operational figures and clearly acknowledged the specialty-product loss and the difficulty of meeting the prior-year revenue level. However, earlier confidence in specialty-polymer growth and FY27 performance has had to be revised, and Elite land timing has slipped across calls. Confidence in Loop funding and the claim of being largely insulated from raw-material volatility deserve scrutiny against the disclosed funding conditions and increased working-capital burden.

e. Evolution of Key Themes

Film demand and margins — Improving: Recovery followed the FY26 downturn; current performance is stronger year on year, though sequential EBITDA declined.
VAS mix — Improving: Share rose from roughly 23–25% in FY26 calls to 27% in H1 FY27; approvals remain a constraint.
Specialty polymers — Deteriorating: Strong FY26 growth gave way to a sharp decline after a major customer changed chemistry; pipeline recovery is not immediate.
Debt and working capital — Deteriorating: Repayments continue, but higher working-capital needs lifted borrowings and delayed visible deleveraging.
Elite execution — Delayed / uncertain: Offtake validation has strengthened, but land and partner-funding milestones remain outstanding.

f. Additional Insights

The earlier specialty-polymer growth story depended more heavily on a small set of high-margin products than the headline growth suggested; the current loss exposes that vulnerability.
Film-margin recovery appears more exposed to external conditions than the strategic narrative implies: anti-dumping implementation, demand-supply balance and VAS approvals all matter.
Management’s debt-reduction narrative increasingly relies on working capital normalizing, not only on scheduled loan repayment.
Elite’s customer validation is meaningful, but the project’s delivery timetable has become a more persistent execution risk than the earlier strategic framing suggested.

Film Recovery Faces Specialty Polymer Slump and Rising Debt